The tensile fatigue behaviour of ultra-high performance fibre reinforced concrete (UHPFRC) under constant amplitude fatigue cycles is presented. Three series of uniaxial tensile fatigue tests up to a maximum of 10 million cycles were conducted with the objective to determine the endurance limit of UHPFRC that was supposed to exist for this material. The fatigue tests reveal that an endurance limit exists in all three domains of UHPFRC tensile behaviour at S-ratios ranging from 0.70 to 0.45 with S being the ratio of the maximum fatigue stress to the elastic limit strength of UHPFRC. Rather large variation in local specimen deformations indicates significant stress and deformation redistribution capacity of the UHPFRC bulk material enhancing the fatigue behaviour. The fatigue fracture surface of UHPFRC shows features of the fatigue fracture surfaces of steel, i.e. fatigue crack propagation is identified by a smooth surface while final fracture leads to rather rough surface. Various fatigue damaging mechanisms due to fretting and grinding as well as tribocorrosion are identified.

a b s t r a c tUltra-High Performance Fibre Reinforced Concrete (UHPFRC) combined with steel rebars, subsequently called R-UHPFRC, is a promising building material implying a novel technology for the improvement of concrete structures. Steel rebars enhance effectively the resistance of UHPFRC while reducing variability in the tensile behaviour of monolithic UHPFRC due to variation in fibre distribution and orientation. When a thin layer of R-UHPFRC is overlaid on top of a concrete bridge deck slab, it is subjected to repeating wheel loads and fatigue limit state needs to be considered. This paper presents the results of tensile fatigue tests on R-UHPFRC elements for the determination of its fatigue behaviour. Experimental results show a fatigue endurance limit at 10 million cycles at a solicitation level of S = 0.54 for S being the ratio between the maximum fatigue force and the ultimate strength. Over the fatigue life of the specimens, stress was transferred from UHPFRC to steel rebars. Fatigue resistance of R-UHPFRC shows that it has a significant potential for fatigue strengthening of reinforced concrete structural elements like bridge deck slabs.

No abstract

No abstract

Off-pump coronary artery bypass grafting (OPCAB) in patients with acute myocardial infarction (AMI) is difficult because of circulatory deterioration during displacement of the heart. At our institution, we performed minimally circulatory-assisted on-pump beating coronary artery bypass grafting (MICAB) in these patients. During MICAB, support flow was controlled at a minimal level to maintain a systemic blood pressure of approximately 100 mm Hg and a pulmonary arterial systolic pressure of <30 mm Hg, providing optimal pulsatile circulation for end-organ perfusion and prevention of heart congestion. From September 2006 to March 2012, MICAB was performed in 37 patients. Either emergent or urgent MICAB was performed in 27 patients following AMI because of hemodynamic instability during reconstruction. Elective MICAB was performed in the remaining 10 patients because of dilated left ventricle (LV) or small target coronary arteries. The details of bypass grafts, perioperative renal function, and early and mid-term morbidity and mortality were compared between the patients who received MICAB and the 37 consecutive patients who underwent OPCAB during the study period at our hospital. The assist flow indices (actual support flow/body surface area) during anastomosis to the left anterior descending artery, left circumflex artery, and right coronary artery were 0.95 ± 0.48 L/min/m , 1.32 ± 0.53 L/min/m , and 1.15 ± 0.47 L/min/m , respectively, in the emergent and urgent patients following AMI, and 0.44 ± 0.39 L/min/m , 1.25 ± 0.39 L/min/m , and 1.14 ± 0.43 L/min/m , respectively, in the elective patients with either dilated LVs or small target vessels. The lowest mixed venous oxygen saturation during pump support in the MICAB group was significantly higher than that in the OPCAB group (83.8 ± 10.8%, 71.6 ± 7.5%, P < 0.001). Comparing MICAB and OPCAB, the median number of distal bypass grafts for both groups was 4 (25th, 75th percentile: 3, 4) (P = 0.558); the complete revascularization rates were 94.6 and 97.3%, respectively (not significant [NS]); the acute patency rates were 98.9 and 99.2%, respectively (NS); and the 30-day mortality rates were 2.7 and 0%, respectively (NS). No instances of either cerebrovascular complications or newly occurring postoperative renal failure were noted in either group. There were no statistically significant differences between the groups with respect to early and mid-term results (freedom from all-cause death: 82.9 vs. 86.5%, respectively, and freedom from cardiac events at 3 years: 96.4 vs. 96.4%, respectively). MICAB is a safe alternative to OPCAB, particularly in patients with AMI and dilated LV. MICAB is associated with high rates of complete revascularization and acute graft patency, adequate preservation of end-organ function, and early and mid-term results comparable with those observed following OPCAB.